ORIGINAL RESEARCH
Published on 16 May 2025
Switching from intravenous to subcutaneous infliximab in patients with immune mediated diseases in clinical remission
doi 10.3389/fmed.2025.1583401
- 314 views
- Frontiers in Pharmacology
- Pharmacoepidemiology
- Research Topics
- Biologic Drugs for immune-mediated inflammatory diseases (IMIDs) and Vaccines for infections: Validation, Drug-Utilization, Effectiveness, Regulation, Costs, and Safety in the real world
Biologic Drugs for immune-mediated inflammatory diseases (IMIDs) and Vaccines for infections: Validation, Drug-Utilization, Effectiveness, Regulation, Costs, and Safety in the real world
48
Total downloads
898
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Published in
Frontiers in Pharmacology
Pharmacoepidemiology
Participating Journals
Frontiers in Public Health
- 3.0 impact factor
- 4.8 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: